Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PhaseBio Pharmaceuticals
Biotech
PhaseBio blames COVID-19 disruption as heart study axed
PhaseBio is blaming the impact of COVID-19 on manufacturing for the decision to end development of a midstage cardiovascular disease treatment.
Annalee Armstrong
Dec 21, 2021 9:17am
PhaseBio shows Brilinta reversal agent can work in an emergency
Nov 15, 2021 11:31am
PhaseBio's Brilinta reversal agent wins midstage test
Nov 3, 2021 10:16am
PhaseBio taps a manufacturing partner for Brilinta-reversing med
Mar 11, 2021 9:50am
PhaseBio eyes phase 2 for Brilinta-reversing drug
Mar 19, 2019 9:33am
PhaseBio nets $34M to advance Brilinta reversal agent, PAH drug
Sep 5, 2018 8:00am
